Dori Germolec, Ph.D., is a biologist in the Toxicology Branch of the National Toxicology Program at the National Institute of Environmental Health Sciences. From 1995 to 2005 Germolec served as the group leader of the Environmental Immunology Laboratory within the Laboratory of Molecular Toxicology at the NIEHS. She currently serves as the Immunology discipline leader for the National Toxicology Program (NTP) and as the lead toxicologist for NTP studies on the toxicity of Resveratrol and mold exposures. She serves as the project officer for the NTP’s contractual efforts to validate test methods and to assess the potential for chemicals to modulate immune responses in rodent models (N01-ES-55538). She also coordinates an Interagency Agreement with NIOSH which evaluates immune measures and genetic susceptibility in occupational settings (Y1-ES0001-07).
Her research interests include the following topics:
investigating the interaction between environmental, industrial, and pharmacologic agents and the immune system
defining the cellular and molecular role of cytokines in toxicity in a variety of organ systems including the skin, lung and immune tissues
Her scientific investigations have resulted in over 100 publications in various areas of toxicology, resulting in the receipt of an NIH Merit Award and The Society of Toxicology Best Publication Award in 1995. In 2004 she received the Outstanding Young Investigator Award from the Immunotoxicology Specialty Section of the SOT. She is an adjunct assistant professor in the department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University. Germolec is active in the Society of Toxicology, as past president of the Immunotoxicology Specialty Section, Program Committee member (2003-2006) and editorial board member. She received an M.A. in physical anthropology from Duke University in 1983 and a Ph.D. in toxicology from North Carolina State University in 1995. She joined NIEHS in 1985.
Murphy-Ryan M, Patterson R, Germolec D. Comparison of taq enzyme preparations in multiplex RT-PCR. Vertices 2006 1 (17-19). [Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=)
Luebke RW, Holsapple MP, Ladics GS, Luster MI, Selgrade M, Smialowicz RJ, Woolhiser MR, Germolec DR. Immunotoxicogenomics: the potential of genomics technology in the immunotoxicity risk assessment process.
Toxicol Sci.. 2006. Nov 94(1):22-7.
Carey MA, Bradbury JA, Seubert JM, Langenbach R, Zeldin DC, Germolec DR. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 Deficiency on the host response to influenza A viral infection. J Immunol. 2005 Nov 15;175(10):6878-84.
Guo TL, Chi RP, Germolec DR, White KL Jr. Stimulation of the Immune Response in B6C3F1 Mice by Genistein Is Affected by Exposure Duration, Gender, and Litter Order. J Nutr. 2005 Oct;135(10):2449-56.
Prater MR, Johnson VJ, Germolec DR, Luster MI, Holladay SD. Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. Vaccine. 2005 Sep 3.
Guo TL, Germolec DR, Musgrove DL, Delclos KB, Newbold RR, Weis C, White KL Jr. Myelotoxicity in genistein-, nonylphenol-, methoxychlor-, vinclozolin- or ethinyl estradiol-exposed F1 generations of Sprague-Dawley rats following developmental and adult exposures. Toxicology. 2005 Aug 1;211(3):207-19.
Xie Y, Trouba KJ, Liu J, Waalkes MP, Germolec DR. Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice. Environ Health Perspect. 2004 Aug;112(12):1255-63.
Germolec DR, Kashon M, Nyska A, Kuper CF, Portier C, Kommineni C, Johnson KA, Luster MI. The accuracy of extended histopathology to detect immunotoxic chemicals. Toxicol Sci. 2004 Dec;82(2):504-14. Epub 2004 Sep 1.
Blood-Siegfried J, Nyska A, Geisenhoffer K, Lieder H, Moomaw C, Cobb K, Shelton B, Coombs W, Germolec D. Alteration in regulation of inflammatory response to influenza a virus and endotoxin in suckling rat pups: a potential relationship to sudden infant death syndrome. FEMS Immunol Med Microbiol. 2004 Sep 1;42(1):85-93.
Patterson R, Vega L, Trouba K, Bortner C, Germolec D Arsenic-induced alterations in the contact hypersensitivity response in Balb/c mice. Toxicol Appl Pharmacol. 2004 Aug 1;198(3):434-43.
Cooper GS, Martin SA, Longnecker MP, Sandler DP, Germolec DR. Associations between plasma DDE levels and immunologic measures in African-American farmers in North Carolina. Environ Health Perspect. 2004 Jul;112(10):1080-4.
Germolec DR. Sensitivity and predictivity in immunotoxicity testing: immune endpoints and disease resistance. Toxicol Lett. 2004 Apr 1;149(1-3):109-14.
Trouba KJ, Germolec DR. Micromolar concentrations of sodium arsenite induce cyclooxygenase-2 expression and stimulate p42/44 mitogen-activated protein kinase phosphorylation in normal human epidermal keratinocytes. Toxicol Sci. 2004 Jun;79(2):248-57.
Blood-Siegfried J , Rambaud C, Nyska A , Germolec DR. Evidence for infection, inflammation and shock in sudden infant death: parallels between a neonatal rat model fo sudden death and infants who died of sudden infant death syndrome. Innate immunity 2008 Jun;14(3):145-152.
Valenzuela OL, Germolec DR, Borja-Aburto VH, Contreras-Ruiz J, García-Vargas GG , Del Razo LM. Chronic arsenic exposure increases TGFalpha concentration in bladder urothelial cells of Mexican populations environmentally exposed to inorganic arsenic. Toxicol Appl Pharmacol. 2007 Aug;222(3):264-270.